Biotechnology
Compare Stocks
5 / 10Stock Comparison
NTRB vs PRGO vs HLN vs DARE vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Biotechnology
Medical - Distribution
NTRB vs PRGO vs HLN vs DARE vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Biotechnology | Medical - Distribution |
| Market Cap | $46M | $1.61B | $41.45B | $25M | $92.15B |
| Revenue (TTM) | $2M | $4.18B | $22.01B | $-57K | $403.43B |
| Net Income (TTM) | $-8M | $-1.82B | $3.18B | $-17M | $4.76B |
| Gross Margin | 24.9% | 34.2% | 63.9% | -1461.1% | 3.6% |
| Operating Margin | -408.4% | -4.1% | 21.4% | -2396.9% | 1.5% |
| Forward P/E | — | 5.6x | 22.2x | — | 19.3x |
| Total Debt | $210K | $3.97B | $8.59B | $1M | $7.39B |
| Cash & Equiv. | $5M | $532M | $1.32B | $16M | $5.69B |
NTRB vs PRGO vs HLN vs DARE vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 22 | May 26 | Return |
|---|---|---|---|
| Nutriband Inc. (NTRB) | 100 | 86.3 | -13.7% |
| Perrigo Company plc (PRGO) | 100 | 28.0 | -72.0% |
| Haleon plc (HLN) | 100 | 132.4 | +32.4% |
| Daré Bioscience, In… (DARE) | 100 | 21.8 | -78.2% |
| McKesson Corporation (MCK) | 100 | 220.2 | +120.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NTRB vs PRGO vs HLN vs DARE vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NTRB lags the leaders in this set but could rank higher in a more targeted comparison.
PRGO is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Beta 1.18, yield 9.8%, current ratio 2.76x
- Lower P/E (5.6x vs 22.2x)
- 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
HLN ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 0.06, Low D/E 52.2%, current ratio 0.92x
- 14.5% margin vs DARE's -414.3%
- 10.0% ROA vs NTRB's -101.9%, ROIC 7.6% vs -270.2%
Among these 5 stocks, DARE doesn't own a clear edge in any measured category.
MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs HLN's 31.7%
- PEG 0.49 vs HLN's 2.63
- 16.2% revenue growth vs DARE's -99.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs DARE's -99.7% | |
| Value | Lower P/E (5.6x vs 22.2x) | |
| Quality / Margins | 14.5% margin vs DARE's -414.3% | |
| Stability / Safety | Beta 0.04 vs NTRB's 1.20 | |
| Dividends | 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +4.6% vs PRGO's -51.2% | |
| Efficiency (ROA) | 10.0% ROA vs NTRB's -101.9%, ROIC 7.6% vs -270.2% |
NTRB vs PRGO vs HLN vs DARE vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NTRB vs PRGO vs HLN vs DARE vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MCK leads in 2 of 6 categories
HLN leads 1 • PRGO leads 1 • NTRB leads 0 • DARE leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HLN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK and DARE operate at a comparable scale, with $403.4B and -$57,130 in trailing revenue. HLN is the more profitable business, keeping 14.5% of every revenue dollar as net income compared to DARE's -414.3%. On growth, MCK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $4.2B | $22.0B | -$57,130 | $403.4B |
| EBITDAEarnings before interest/tax | -$8M | $58M | $5.3B | -$16M | $6.8B |
| Net IncomeAfter-tax profit | -$8M | -$1.8B | $3.2B | -$17M | $4.8B |
| Free Cash FlowCash after capex | -$5M | $108M | $3.1B | -$7M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +24.9% | +34.2% | +63.9% | -1461.1% | +3.6% |
| Operating MarginEBIT ÷ Revenue | -4.1% | -4.1% | +21.4% | -2396.9% | +1.5% |
| Net MarginNet income ÷ Revenue | -4.0% | -43.5% | +14.5% | -414.3% | +1.2% |
| FCF MarginFCF ÷ Revenue | -2.5% | +2.6% | +14.2% | +492.8% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -37.6% | -7.2% | -0.4% | -94.6% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +84.4% | -56.4% | +18.8% | +49.2% | +37.0% |
Valuation Metrics
PRGO leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 19.0x trailing earnings, HLN trades at a 35% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HLN's 2.25x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $46M | $1.6B | $41.4B | $25M | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $42M | $5.1B | $51.3B | $11M | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.47x | -1.14x | 19.01x | -6.06x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x | 22.22x | — | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.25x | — | 0.75x |
| EV / EBITDAEnterprise value multiple | — | 7.42x | 13.62x | — | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 22.66x | 0.38x | 2.83x | 2587.71x | 0.26x |
| Price / BookPrice ÷ Book value/share | 6.61x | 0.55x | 1.87x | — | — |
| Price / FCFMarket cap ÷ FCF | — | 11.12x | 15.47x | 5.25x | 17.63x |
Profitability & Efficiency
MCK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-6 for DARE. NTRB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), HLN scores 8/9 vs NTRB's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -118.3% | -50.7% | +19.9% | -6.1% | +3.0% |
| ROA (TTM)Return on assets | -101.9% | -19.8% | +10.0% | -56.8% | +5.7% |
| ROICReturn on invested capital | -2.7% | +3.7% | +7.6% | — | +5.4% |
| ROCEReturn on capital employed | -125.5% | +4.3% | +8.6% | -36.2% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 8 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.03x | 1.35x | 0.52x | — | — |
| Net DebtTotal debt minus cash | -$4M | $3.4B | $7.3B | -$14M | $1.7B |
| Cash & Equiv.Liquid assets | $5M | $532M | $1.3B | $16M | $5.7B |
| Total DebtShort + long-term debt | $209,629 | $4.0B | $8.6B | $1M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | -369.11x | -7.20x | 7.80x | -35.60x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $1,757 for DARE. Over the past 12 months, MCK leads with a +4.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs DARE's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -14.4% | -13.5% | -5.6% | +49.2% | -8.5% |
| 1-Year ReturnPast 12 months | -34.4% | -51.2% | -11.7% | +0.7% | +4.6% |
| 3-Year ReturnCumulative with dividends | +10.8% | -58.1% | +10.4% | -75.8% | +106.4% |
| 5-Year ReturnCumulative with dividends | -34.0% | -60.1% | +31.7% | -82.4% | +286.9% |
| 10-Year ReturnCumulative with dividends | -34.0% | -77.7% | +31.7% | -99.0% | +348.1% |
| CAGR (3Y)Annualised 3-year return | +3.5% | -25.2% | +3.4% | -37.6% | +27.3% |
Risk & Volatility
Evenly matched — HLN and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than NTRB's 1.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HLN currently trades 81.5% from its 52-week high vs DARE's 31.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.20x | 1.18x | 0.06x | 0.48x | 0.04x |
| 52-Week HighHighest price in past year | $11.68 | $28.44 | $11.42 | $9.19 | $999.00 |
| 52-Week LowLowest price in past year | $3.42 | $9.23 | $8.71 | $1.27 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +32.4% | +41.2% | +81.5% | +31.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 50.8 | 60.9 | 36.0 | 70.2 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 11K | 3.4M | 8.0M | 581K | 757K |
Analyst Outlook
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PRGO as "Hold", HLN as "Buy", MCK as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 9.6% for HLN (target: $10). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | — | Buy |
| Price TargetConsensus 12-month target | — | $20.00 | $10.20 | — | $1006.50 |
| # AnalystsCovering analysts | — | 36 | 4 | — | 31 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% | +1.9% | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 10 | 2 | — | 17 |
| Dividend / ShareAnnual DPS | — | $1.15 | $0.13 | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +2.1% | 0.0% | +3.4% |
MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). HLN leads in 1 (Income & Cash Flow). 2 tied.
NTRB vs PRGO vs HLN vs DARE vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NTRB or PRGO or HLN or DARE or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate Haleon plc (HLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NTRB or PRGO or HLN or DARE or MCK?
On trailing P/E, Haleon plc (HLN) is the cheapest at 19.
0x versus McKesson Corporation at 29. 2x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Haleon plc's 2. 63x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NTRB or PRGO or HLN or DARE or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: MCK returned +348. 1% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NTRB or PRGO or HLN or DARE or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Nutriband Inc. 's 1. 20β — meaning NTRB is approximately 2693% more volatile than MCK relative to the S&P 500. On balance sheet safety, Nutriband Inc. (NTRB) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — NTRB or PRGO or HLN or DARE or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NTRB or PRGO or HLN or DARE or MCK?
Haleon plc (HLN) is the more profitable company, earning 15.
1% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HLN leads at 22. 4% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — HLN leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NTRB or PRGO or HLN or DARE or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Haleon plc's 2. 63x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 22. 2x for Haleon plc — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — NTRB or PRGO or HLN or DARE or MCK?
In this comparison, PRGO (9.
8% yield), HLN (1. 9% yield), MCK (0. 4% yield) pay a dividend. NTRB, DARE do not pay a meaningful dividend and should not be held primarily for income.
09Is NTRB or PRGO or HLN or DARE or MCK better for a retirement portfolio?
For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
06), 1. 9% yield). Both have compounded well over 10 years (HLN: +31. 7%, NTRB: -34. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NTRB and PRGO and HLN and DARE and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NTRB is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; DARE is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. PRGO, HLN pay a dividend while NTRB, DARE, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.